Clinical Trial Search

Primary: Progression-free Survival (PFS) According to Grade of Rash — 2.16; 6.62; 10.00; 15.28 months — p=0.005

Primary: Overall Response Rate — 11; 2 Participants

Primary: Evaluate the Effects of Ketamine on Depressive Symptomatology by Measuring Change in Score on the Montgomery-Asberg Depressive Rating Scale — 28.82; 25.20 units on a scale

Primary: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort — 1.7; 3.0 Percentage of Participants — p=0.282

Primary: Change From Baseline in Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at Week 12 — -0.77; -1.38; -1.36; -1.69 score on a scale — p=0.086

Primary: Total Number of Ranibizumab Injections in Each of the Two Cohorts in a 36 Month Period — 24.4; 27.1 injections

Primary: Subjective Marijuana Effects — 13; 15; 16; 16 units on a scale (0-100mm)

Primary: Percentage of Participants With Complete Hives Response (HSS7=0) — 30.2; 51.2; 42.4; 25.9 Percentage of participants — p=<.05

Primary: Maximum Tolerated Dose of High-dose Cyclophosphamide as Determined by Number of Participants Who Tolerated Each Dose of Cyclophosphamide — 4; 4; 2 Participants

Primary: Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (hSBA-MenA, hSBA-MenC, hSBA-MenW -135…

Primary: Percentage of Participants Who Experienced at Least One Treatment-emergent Adverse Event (AE) — 50.0; 0.0; 33.3; 33.3 Percentage of Participants

Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 14; 20; 21; 18 Participants

Primary: Levels of Proviral DNA in Peripheral Blood Mononuclear Cells (PBMC) (log10) — 1.88; 1.92 log10(copies/mL)

Primary: Progression-free Survival Per RECIST, v. 1.1 (PFS1) — 11.000 months

Primary: HbA1c — -0.5; -0.6; -0.9; -1.0 Percentage (%) of HbA1c — p=<0.0001